Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
With an estimated $5.4 billion in sunk costs in Brilinta, AstraZeneca will likely never turn a profit on the blood thinner with generics expected to hit the market in…
Research firm EvaluatePharma sees global sales of Enhertu in the $2 billion range in 2024, and Fumiyoshi Sakai of Credit Suisse Securities (Japan) predicts peak annual…
Analysts don’t see Libtayo making a big impression in the field, however – Evaluate Pharma forecasts the drug reaching revenues of just $600m by 2024, far behind Merck…
Zepsyre carries 2024 sales forecasts of $163 million, implying an NPV of $600 million, according to EvaluatePharma
Novo Nordisk shares recently popped, and Evaluate Pharma speculates that this was related to the company’s participation in the trial after the Danish newspaper Børsen…
The sell-side expects tafasitamab to generate 2024 revenue of $661 million, according to EvaluatePharma consensus.
EvaluatePharma has previously predicted that Ozempic could become a $2.2bn product by 2022, but other analysts think it could go even higher, perhaps reaching $3bn plus…
By 2024, the cost of gene therapies is expected to reach more than $16 billion in the United States, according to EvaluatePharma, which is both good news and bad news…
Bristol-Myers Squibb Co., fresh off completing one of the largest drug-industry mergers ever, is counting on the acquisition to pay off quickly with new products and…
The British company Evaluate Pharma also expects additional sales of around $ 50 billion (around 45 billion euros) for the global pharmaceutical industry this year.